echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > With $770 million in access to a wide range of ophthalmic drugs, Alcon expands its drug pipeline

    With $770 million in access to a wide range of ophthalmic drugs, Alcon expands its drug pipeline

    • Last Update: 2022-09-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Alcon and Aerie Pharmaceuticals announced that they have reached an agreement that Alcon will spend about $770 million to acquire Aerie


    Aerie's research therapy AR-15512 is a small molecule TRPM8 ion channel agonist that represents an innovative mechanism


    In a Phase 2 clinical trial, AR-15512 significantly increased the level of tear secretion in patients after 1 or 14 days of use, while the patients' symptoms were significantly relieved


    ▲Aerie product pipeline (Image source: Aerie official website)

    "Alcon is committed to developing innovative ophthalmic therapies, especially in the areas of


    Original english:

    Original english:
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.